Chloramphenicol palmitate API Manufacturers & Suppliers

Chloramphenicol palmitate is a chemically modified derivative of chloramphenicol, classified within the class of nitrobenzene compounds. Structurally, it contains a benzene ring substituted with a nitro group, typical of nitrobenzenes, and is further characterized by esterification with palmitic acid. This modification influences its physicochemical properties relative to the parent compound.

While specific clinical indications for chloramphenicol palmitate are not extensively detailed, it is generally used in veterinary medicine, reflecting its approval status in this domain. The parent molecule, chloramphenicol, is known for its broad-spectrum antibacterial activity, functioning primarily through inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing peptide bond formation. As an ester prodrug, chloramphenicol palmitate is enzymatically hydrolyzed in vivo to release the active chloramphenicol moiety, thereby enabling systemic antibacterial effects.

Key pharmacokinetic data specific to chloramphenicol palmitate remain limited; however, the ester form is designed to improve oral bioavailability and reduce local gastrointestinal irritation compared to chloramphenicol base. After administration, absorption leads to conversion to chloramphenicol, which is widely distributed in body tissues and fluids. Metabolism occurs primarily in the liver via conjugation, and the compound is eliminated through renal and biliary excretion.

Safety considerations for chloramphenicol include known risks such as bone marrow suppression and aplastic anemia associated with the parent drug. Due to chloramphenicol’s potential for serious hematologic toxicity, use is generally restricted to specific indications where alternative therapies are unsuitable, particularly in veterinary contexts. Careful monitoring and adherence to regulatory guidelines are essential to mitigate safety risks.

From an API sourcing perspective, procuring chloramphenicol palmitate requires confirmation of stringent quality controls, including compliance with pharmacopeial standards and verification of purity, residual solvents, and absence of contaminants. Given its prodrug nature and potential for conversion to an active nitrobenzene compound, manufacturing processes must ensure consistent esterification and stability to guarantee reliable clinical performance and regulatory acceptance.